Market Overview

Dawson James Securities Reiterates Market Outperform Rating, $4 PT on Keryx Biopharmaceuticals

Share:
Related KERX
5 Biotech Stocks Roth Capital Analysts Are Watching
UPDATE: Keryx Biopharmaceuticals Posts Q4 Loss

In a report published Wednesday, Dawson James Securities reiterated its Market Outperform rating and $4.00 price target on Keryx Biopharmaceuticals (NASDAQ: KERX).

Dawson James Securities noted, “We maintain our Market Outperform rating and $4 price target on KERX shares. We derive our $4 price target by the synthesis of our DCF valuation ($3.73), comparables analysis (~$5.00), and our standardized CAGR methodology ($5.77). Risks to our valuation included clinical and regulatory, partnering, competitive, reimbursement, intellectual property and financial.”

Keryx Biopharmaceuticals closed on Tuesday at $2.93.

Latest Ratings for KERX

DateFirmActionFromTo
Mar 2015Stifel NicolausMaintainsBuy
Nov 2014Maxim GroupMaintainsBuy
Aug 2014FBR CapitalInitiates Coverage onMarket Perform

View More Analyst Ratings for KERX
View the Latest Analyst Ratings

Posted-In: Dawson James SecuritiesAnalyst Color Reiteration Analyst Ratings

 

Related Articles (KERX)

Around the Web, We're Loving...